Skip to main content
Top
Published in: Journal of Neuro-Oncology 1/2010

Open Access 01-03-2010 | Laboratory Investigation - Human/Animal Tissue

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

Authors: Sean M. McBride, Daniel A. Perez, Mei-Yin Polley, Scott R. Vandenberg, Justin S. Smith, Shichun Zheng, Kathleen R. Lamborn, John K. Wiencke, Susan M. Chang, Michael D. Prados, Mitchel S. Berger, David Stokoe, Daphne A. Haas-Kogan

Published in: Journal of Neuro-Oncology | Issue 1/2010

Login to get access

Abstract

Recent evidence suggests the Akt-mTOR pathway may play a role in development of low-grade gliomas (LGG). We sought to evaluate whether activation of this pathway correlates with survival in LGG by examining expression patterns of proteins within this pathway. Forty-five LGG tumor specimens from newly diagnosed patients were analyzed for methylation of the putative 5′-promoter region of PTEN using methylation-specific PCR as well as phosphorylation of S6 and PRAS40 and expression of PTEN protein using immunohistochemistry. Relationships between molecular markers and overall survival (OS) were assessed using Kaplan-Meier methods and exact log-rank test. Correlation between molecular markers was determined using the Mann-Whitney U and Spearman Rank Correlation tests. Eight of the 26 patients with methylated PTEN died, as compared to 1 of 19 without methylation. There was a trend towards statistical significance, with PTEN methylated patients having decreased survival (P = 0.128). Eight of 29 patients that expressed phospho-S6 died, whereas all 9 patients lacking p-S6 expression were alive at last follow-up. There was an inverse relationship between expression of phospho-S6 and survival (P = 0.029). There was a trend towards decreased survival in patients expressing phospho-PRAS40 (P = 0.077). Analyses of relationships between molecular markers demonstrated a statistically significant positive correlation between expression of p-S6(235) and p-PRAS40 (P = 0.04); expression of p-S6(240) correlated positively with PTEN methylation (P = 0.04) and negatively with PTEN expression (P = 0.03). Survival of LGG patients correlates with phosphorylation of S6 protein. This relationship supports the use of selective mTOR inhibitors in the treatment of low grade glioma.
Literature
1.
go back to reference Agulnik M, Mason WP (2006) The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol Oncol Clin North Am 20:1249–1266CrossRefPubMed Agulnik M, Mason WP (2006) The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol Oncol Clin North Am 20:1249–1266CrossRefPubMed
2.
go back to reference Rasheed BK, McLendon RE, Herndon JE et al (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1330PubMed Rasheed BK, McLendon RE, Herndon JE et al (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1330PubMed
3.
go back to reference Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMed Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMed
4.
go back to reference Varela M, Ranuncolo SM, Morand A et al (2004) EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. J Surg Oncol 86:34–40CrossRefPubMed Varela M, Ranuncolo SM, Morand A et al (2004) EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. J Surg Oncol 86:34–40CrossRefPubMed
5.
go back to reference Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E (2006) Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir 67:204–209CrossRefPubMed Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E (2006) Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir 67:204–209CrossRefPubMed
6.
go back to reference Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385CrossRefPubMed Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385CrossRefPubMed
7.
go back to reference Contreras AG, Dormond O, Edelbauer M et al (2008) mTOR-understanding the clinical effects. Transplant Proc 40:S9–S12CrossRefPubMed Contreras AG, Dormond O, Edelbauer M et al (2008) mTOR-understanding the clinical effects. Transplant Proc 40:S9–S12CrossRefPubMed
8.
go back to reference Geissler EK (2008) The impact of mTOR inhibitors on the development of malignancy. Transplant Proc 40:S32–S35CrossRefPubMed Geissler EK (2008) The impact of mTOR inhibitors on the development of malignancy. Transplant Proc 40:S32–S35CrossRefPubMed
9.
go back to reference Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348CrossRefPubMed Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348CrossRefPubMed
10.
go back to reference Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148–159CrossRefPubMed Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148–159CrossRefPubMed
11.
go back to reference Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24:893–900PubMed Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24:893–900PubMed
12.
go back to reference Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319CrossRefPubMed Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319CrossRefPubMed
13.
go back to reference Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8CrossRefPubMed Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8CrossRefPubMed
14.
go back to reference Volarevic S, Thomas G (2001) Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 65:101–127CrossRefPubMed Volarevic S, Thomas G (2001) Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 65:101–127CrossRefPubMed
15.
go back to reference Wang L, Harris TE, Lawrence JC (2008) Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 283:15619–15627CrossRefPubMed Wang L, Harris TE, Lawrence JC (2008) Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 283:15619–15627CrossRefPubMed
16.
go back to reference Dancey JE (2006) MTOR and related pathways. Cancer Biol Ther 5(9):1065–1073PubMed Dancey JE (2006) MTOR and related pathways. Cancer Biol Ther 5(9):1065–1073PubMed
Metadata
Title
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
Authors
Sean M. McBride
Daniel A. Perez
Mei-Yin Polley
Scott R. Vandenberg
Justin S. Smith
Shichun Zheng
Kathleen R. Lamborn
John K. Wiencke
Susan M. Chang
Michael D. Prados
Mitchel S. Berger
David Stokoe
Daphne A. Haas-Kogan
Publication date
01-03-2010
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-0004-4

Other articles of this Issue 1/2010

Journal of Neuro-Oncology 1/2010 Go to the issue